image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.55
7.64 %
$ 135 M
Market Cap
-1.48
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LUCD stock under the worst case scenario is HIDDEN Compared to the current market price of 1.55 USD, Lucid Diagnostics Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LUCD stock under the base case scenario is HIDDEN Compared to the current market price of 1.55 USD, Lucid Diagnostics Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LUCD stock under the best case scenario is HIDDEN Compared to the current market price of 1.55 USD, Lucid Diagnostics Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart LUCD

image
$1.6$1.6$1.5$1.5$1.4$1.4$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.715 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
4.35 B REVENUE
178895.06%
-46.1 B OPERATING INCOME
-94887.83%
-45.5 B NET INCOME
-86348.56%
-44.1 B OPERATING CASH FLOW
-134403.46%
-646 M INVESTING CASH FLOW
-292207.69%
48.2 B FINANCING CASH FLOW
163674.61%
1.2 M REVENUE
2.13%
-12.4 M OPERATING INCOME
-5.82%
-11.5 M NET INCOME
6.71%
-9.87 M OPERATING CASH FLOW
2.99%
-259 K INVESTING CASH FLOW
99.93%
18 M FINANCING CASH FLOW
19047.87%
Balance Sheet Lucid Diagnostics Inc.
image
Current Assets 25.1 B
Cash & Short-Term Investments 22.4 B
Receivables 405 K
Other Current Assets 2.79 B
Non-Current Assets 5.57 B
Long-Term Investments 0
PP&E 3.7 B
Other Non-Current Assets 1.87 B
72.79 %9.08 %12.04 %6.08 %Total Assets$30.7b
Current Liabilities 23.5 B
Accounts Payable 1.24 M
Short-Term Debt 855 M
Other Current Liabilities 22.7 B
Non-Current Liabilities 1.8 M
Long-Term Debt 20.4 B
Other Non-Current Liabilities -20.4 B
96.35 %86.72 %Total Liabilities$23.5b
EFFICIENCY
Earnings Waterfall Lucid Diagnostics Inc.
image
Revenue 4.35 B
Cost Of Revenue 7.1 B
Gross Profit -2.75 B
Operating Expenses 43.3 B
Operating Income -46.1 B
Other Expenses -523 M
Net Income -45.5 B
10b10b00(10b)(10b)(20b)(20b)(30b)(30b)(40b)(40b)(50b)(50b)4b(7b)(3b)(43b)(46b)523m(46b)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-63.35% GROSS MARGIN
-63.35%
-1059.64% OPERATING MARGIN
-1059.64%
-1.05% NET MARGIN
-1.05%
-0.84% ROE
-0.84%
-0.15% ROA
-0.15%
-666.61% ROIC
-666.61%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Lucid Diagnostics Inc.
image
00(5b)(5b)(10b)(10b)(15b)(15b)(20b)(20b)(25b)(25b)(30b)(30b)(35b)(35b)(40b)(40b)(45b)(45b)20192019202020202021202120222022202320232024202420252025
Net Income -45.5 B
Depreciation & Amortization 1.17 B
Capital Expenditures 0
Stock-Based Compensation 4.53 M
Change in Working Capital -4.43 M
Others 217 M
Free Cash Flow -44.1 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Lucid Diagnostics Inc.
image
Wall Street analysts predict an average 1-year price target for LUCD of $2.5 , with forecasts ranging from a low of $2 to a high of $3 .
LUCD Lowest Price Target Wall Street Target
2 USD 29.03%
LUCD Average Price Target Wall Street Target
2.5 USD 61.29%
LUCD Highest Price Target Wall Street Target
3 USD 93.55%
Price
Max Price Target
Min Price Target
Average Price Target
333322221111May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Lucid Diagnostics Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference NEW YORK , April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D. , Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 11:00 AM EDT. prnewswire.com - 2 weeks ago
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK , March 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced a campaign, entitled "Embrace the Future", designed to showcase its groundbreaking EsoCheck® Esophageal Cell Collection Device, with Collect+Protect™ Technology, to gastroenterologists and the broader medical community. The campaign will coincide with Esophageal Cancer Awareness Month this April and will be prominently featured at Digestive Disease Week (DDW) 2025, the world's premier meeting for gastroenterologists and other digestive disease professionals, to be held in May. prnewswire.com - 3 weeks ago
Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director, Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG Mike Matson - Needham & Company Anthony Vendetti - Maxim Group Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Fourth Quarter 2024 Business Update Conference Call. At this time, all lines are in listen-only mode. seekingalpha.com - 4 weeks ago
Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Lags Revenue Estimates Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.23 per share a year ago. zacks.com - 4 weeks ago
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24   New sales channel generated over 20 new cash-pay concierge medicine contracts Secured first agreement to pay for EsoGuard under state biomarker legislation Conference call and webcast to be held today, March 24 th at 8:30 AM EDT NEW YORK , March 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast The webcast will take place on Monday, March 24, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. prnewswire.com - 4 weeks ago
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy NEW YORK , March 20, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that a recent update to the National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) focused on Esophageal and Esophagogastric Junction Cancers (Version 1.2025) has added a new section on esophageal precancer (Barrett's Esophagus or BE) screening. The NCCN Guidelines® now reference professional society guidelines on BE screening, including the most recent American College of Gastroenterology (ACG) Clinical Guideline which recommends non-endoscopic biomarker testing, such as Lucid's EsoGuard® Esophageal DNA Test performed on samples collected with its EsoCheck® Esophageal Cell Collection Device, as an acceptable alternative to invasive upper endoscopy to detect esophageal precancer. prnewswire.com - 1 month ago
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , March 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that its ENVET-BE clinical utility study has been accepted for publication in  Gastroenterology & Hepatology —the fifth peer-reviewed publication of clinical utility data for Lucid's EsoGuard® Esophageal DNA Test, and the second to present findings from a real-world screening population. The manuscript, entitled Enhancing the Diagnostic Yield of EGD for Diagnosis of Barrett's Esophagus Through Methylated DNA Biomarker Triage , demonstrates that confirmatory upper endoscopy (EGD) performed in EsoGuard-positive patients had a substantially higher diagnostic yield for detecting esophageal precancer (Barrett's Esophagus or BE) than the expected yield of screening EGD alone in at-risk patients. prnewswire.com - 1 month ago
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test Regional Blue Cross Blue Shield plan will cover non-invasive screening of esophageal precancer and cancer NEW YORK , March 13, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Highmark Blue Cross Blue Shield, an independent licensee of the Blue Cross and Blue Shield Association, has issued a positive coverage policy for non-invasive screening of esophageal precancer and cancer in New York state. The new policy will cover Lucid's EsoGuard® Esophageal DNA Test in patients who meet established criteria for esophageal precancer testing consistent with professional society guidelines. prnewswire.com - 1 month ago
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Monday, March 24, 2025, at 8:30 AM ET. During the call,  Lishan Aklog, M.D. prnewswire.com - 1 month ago
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering NEW YORK , March 5, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per share.   The gross proceeds to the Company from this offering are approximately $15.3 million, before deducting the approximately $0.8 million in placement agent's fees and other offering expenses payable by the Company. prnewswire.com - 1 month ago
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering NEW YORK , March 4, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into subscription agreements with certain accredited investors to sell 13,939,331 shares of common stock at a purchase price of $1.10 per share in a registered direct offering. The gross proceeds to the Company from this offering are expected to be approximately $15.3 million, before deducting the approximately $0.8 million in placement agent's fees and other offering expenses payable by the Company. prnewswire.com - 1 month ago
Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigators NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that a consortium of prestigious academic medical centers, led by principal investigators from Case Western Reserve University (CWRU) and University Hospitals (UH), has been awarded an $8 million National Institutes of Health (NIH) R01 grant to conduct a five-year clinical study designed to evaluate esophageal precancer detection using Lucid's EsoCheck® Esophageal Cell Collection Device and EsoGuard® Esophageal DNA Test  among at-risk individuals without symptoms of chronic gastroesophageal reflux disease (GERD). The study, "A Clinical Trial of Cancer Prevention by Biomarker Based Detections of Barrett's Esophagus and Its Progression," aims to evaluate the effectiveness of EsoCheck and EsoGuard in detecting esophageal precancer (Barrett's Esophagus or BE) to prevent esophageal cancer (EAC) within a non-GERD at-risk population. prnewswire.com - 1 month ago
8. Profile Summary

Lucid Diagnostics Inc. LUCD

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 135 M
Dividend Yield 0.00%
Description Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Contact One Grand Central Place, New York, NY, 10165 https://www.luciddx.com
IPO Date Oct. 14, 2021
Employees 72
Officers Dr. Lishan Aklog M.D. Chairman & Chief Executive Officer Dr. Joseph Willis M.D. Co-founder & Strategic Advisor Helen Moinova Ph.D. Co-Founder & Strategic Advisor Mr. Matthew Riley Director of Investor Relations Dr. Suman M. Verma M.D., Ph.D. Chief Scientific Officer Dr. Amitabh Chak M.D. Co-Founder & Strategic Advisor Dr. Brian J. deGuzman M.D. Chief Technology & Compliance Officer Mr. Shaun M. O'Neill M.B.A. President & Chief Operating Officer Mr. Michael Adam Gordon General Counsel & Secretary Dr. Sanford D. Markowitz M.D., Ph.D. Co-Founder & Strategic Advisor